- The U.S. FDA will conduct an evaluation of its Center for Tobacco Products using outside advisors as the agency aims to meet the challenges of regulation.
- "Challenges lie ahead as we determine how the agency will navigate complex policy issues and determine enforcement activities for an increasing number of novel products that could potentially have significant consequences for public health," FDA Commissioner Robert Califf said in a statement.
- The center was established in 2009.
- The FDA has tapped the Reagan-Udall Foundation to work with a group of outside experts in reporting its findings and recommendations within 60 days of starting the evaluation.
- The evaluation will also include the agency's Human Foods Program.
- Tobacco/vaping stocks: Philip Morris International ( NYSE: PM ), Altria Group ( NYSE: MO ), British American Tobacco ( NYSE: BTI ), Imperial Brands ( OTCQX:IMBBY ), Japan Tobacco ( OTCPK:JAPAY ), Vector Group ( VGR ), RLX Technology ( RLX ).
- Read Seeking Alpha's contributor's The Value Pendulum's assessment of Philip Morris ahead of earnings on July 21 .
For further details see:
FDA conducting evaluation of tobacco division amid 'increasing number of novel products'